{"task_id": "77600604e6a45ebd", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 191/464)", "text": "ND PROGNOSTIC ISSUES (CONT\u2019D)\nMultiple Myeloma\n179\n\n--- Page 201 ---\nMANAGEMENT\nMULTIPLE MYELOMA\n\u0002\nAGE <65 AND OTHERWISE HEALTHY (curative)\ninduction chemotherapy with thalidomide plus\ndexamethasone (first choice), lenalidomide plus\ndexamethasone, pulse dexamethasone, or VAD\n(vincristine, doxorubicin, dexamethasone) \u00033 4\nmonths. If good response, then proceed to high\ndose melphalan followed by autologous stem\ncell transplant. This regimen prolongs survival by\n12 months, but is not curative. Consider tandem\ntransplantation if less than a good partial response\n(i.e. \b90% reduction of monoclonal protein)\n\u0002\nAGE >65 OR COMORBIDITIES (palliative)\nMP (mel\nphalan + prednisone) \u0004 thalidomide. Addition of\ninterferon to MP provides small benefit. If bony\ndisease, add bisphosphonate (alendronate, zole\ndronate). Second line options include thalido\nmide (response \u000530%) + dexamethasone, lena\nlidomide\n+\ndexamethasone,\nbortezomib\n(response \u000530%), dexamethasone alone, and\ninfusional VAD\n\u0002\nSUPPORTIVE\nMEASURES\nhydration\n(>3\nl/day),\nhypercalcemia (hydration, prednisone 25 mg PO\nQID, pamidronate), renal insufficiency (treat\nunderlying cause), infections (antibiotics, consider\nIVIG as last resort if recurrent infections despite\nprophylactic antibiotics), skeletal lesions (pami\ndronate 90 mg IV over 2 h q3 4weeks, radiation,\nvertebroplasty), anemia Hb <90 g/L [ <9 g/dL]\n(transfusions, usually respond to an erythropoiesis\nstimulating agent, although one should exercise\ngreat caution given the increased risk of throm\nboembolism and death), hyperviscosity syn\ndrome (Ostwald viscosimeter >5, plasmapheresis),\nanticoagulation (if on thalidomide/lenalidomide\nand chemotherapy)\nMANAGEMENT (CONT\u2019D)\nSMM\nno treatment. Follow clinically\nMGUS\nno treatment. Follow clinically\nTREATMENT ISSUES\nINDICATIONS FOR TREATING MULTIPLE MYE\nLOMA\n>stage I, increasing level of M protein in\nserum or urine, significant hypercalcemia, anemia,\nrenal insufficiency, lytic bone lesions, extramedullary\nplasmacytoma\nSPECIFIC ENTITIES\nSOLITARY\nPLASMACYTOMA\nOF\nBONE\nsingle\nosteolytic bone lesion with limited amount of mono\nclonal protein in the serum or urine and absence of\ntissue impairment. Radiation is usually treatment of\nchoice and may result in a cure. 80% chance of\ndeveloping multiple myeloma\nAMYLOIDOSIS\nSee p. 420 for more details. Workup\ninclude\nabdominal\nfat\nbiopsy,\nabd\nU/S,\nand\nechocardiogram\nPOEMS SYNDROME\nosteosclerotic myeloma with\nPolyneuropathy,\nOrganomegaly,\nEndocrine\n(dia\nbetes, hypothyroidism, parathyroid hypogonadism,\nHPA), Monoclonal protein, Skin changes (hyperpig\nmentation, hypertrichosis, acrocyanosis, plethora,\nhemangioma/telangiectasia).\nPolyneuropathy\nand\nmonoclonal plasma cell disorder most important\nHYPERVISCOSITY SYNDROME\nIgG >70 g/L [>7 g/\ndL] or IgA >50 g/L [>5 g/dL]. Symptoms include\nfatigue, changes in mental status, focal or non focal\nneurologic changes, visual changes along with reti\nnopathy, angina pectoris, bleeding disorder, cryoglo\nbulin, Raynaud\u2019s phenomenon, or purpuric eruptions\non exposure to the cold\nFebrile Neutropenia\nSee FEBRILE NEUTROPENIA (p. 236)\nHematopoietic Stem Cell Transplant\nCMAJ 2004 170:10\nNEJM 2006 354:17\nTERMINOLOGIES\nALLOGENEIC\nTRANSPLANTATION\n(40%)\nstem\ncells from HLA matched sibling donor (25%) or unre\nlated donor (75%). The main advantage is graft vs.\nleukemia effect (GVL), while the main disadvantage is\ngraft vs. host effect (GVHD)\nTERMINOLOGIES (CONT\u2019D)\nAUTOLOGOUS TRANSPLANTATION (60%)\nstem\ncells from self. The main advantage is lesser toxicity\ncompared to allogeneic transplant, while the main\ndisadvantage is possible contamination of the graft\nwith malignant cells\n180\nHematopoietic Stem Cell Transplant", "text_length": 3672, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 191/464)", "type": "chunk", "chunk_index": 190, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.508320", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.509212", "status": "complete", "chunks_added": 2}